Table 2

Biomarker concentrations at month 2, by baseline vitamin K antagonist treatment group

BiomarkerVKA treatment before randomisationApixabanWarfarinApixaban vs warfarin ratio geometric mean (95% CI)Treatment difference P values
Month 2/baseline geometric mean (95% CI)Month 2 concentration geometric mean (95% CI)Month 2/baseline geometric mean (95% CI)Month 2 concentration geometric mean (95% CI)
F1+2 (pmol/L)No (n=1939)0.75 (0.70 to 0.80)130.1 (121.8 to 138.9)0.41 (0.38 to 0.43)70.8 (66.1 to 75.8)1.84 (1.67 to 2.02)<0.0001
Yes (n=2879)1.41 (1.34 to 1.48)116.1 (110.5 to 122.0)0.63 (0.60 to 0.66)51.7 (49.2 to 54.4)2.24 (2.09 to 2.41)<0.0001
D-dimer (µg/L)No (n=1939)0.77 (0.74 to 0.80)488.1 (471.1 to 505.9)0.62 (0.60 to 0.64)392.6 (378.2 to 407.5)1.24 (1.18 to 1.31)<0.0001
Yes (n=2881)1.10 (1.07 to 1.12)461.8 (450.5 to 473.3)0.89 (0.86 to 0.91)373.0 (363.9 to 382.3)1.24 (1.20 to 1.28)<0.0001
sCD40L (µg/L)No (n=1939)1.09 (1.04 to 1.14)0.63 (0.60 to 0.66)1.07 (1.02 to 1.12)0.62 (0.59 to 0.65)1.02 (0.95 to 1.09)0.5531
Yes (n=2880)1.05 (1.01 to 1.09)0.55 (0.53 to 0.58)1.07 (1.03 to 1.11)0.56 (0.54 to 0.59)0.98 (0.93 to 1.03)0.4931
vWF antigen (kIE/L)No (n=1938)0.80 (0.77 to 0.84)1.01 (0.97 to 1.05)0.83 (0.80 to 0.87)1.05 (1.01 to 1.09)0.96 (0.91 to 1.02)0.1884
Yes (n=2877)0.82 (0.79 to 0.84)1.08 (1.04 to 1.11)0.85 (0.82 to 0.87)1.12 (1.09 to 1.15)0.96 (0.92 to 1.01)0.0843
  • Randomised treatment groups were compared by VKA treatment group using a linear regression model with the logarithm of the month 2 biomarker concentration as dependent variable and the logarithm of baseline biomarker concentration and randomised treatment as independent variables. Model-adjusted estimates are presented as geometric means and treatment group differences as ratios of geometric means.

  • F1+2, fragment 1+2; sCD40L, soluble CD40 ligand; VKA, vitamin K antagonist; vWF, von Willebrand factor.